Therapeutic Response

FLT3 p.D835A status confers therapeutic sensitivity to Gilteritinib in patients with Acute Myeloid Leukemia.

Statements

Source and description
Xospata (gilteritinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to gilteritinib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation, as detected by an FDA-approved test.
Xospata (gilteritinib) [product monograph]. HC. Health Canada approved gilteritinib for the treatment of adult patients who have relapsed or refactory acute myeloid leukemia with a FMS-like tyrosine kinase 3 (FLT3) mutation.